Antiplatelets/Antifibrinolytics Flashcards
1
Q
Antiplatelets:
Medication Classes and Agents
A
- Thromboxane inhibitor
- Aspirin (ASA)
- P2Y12 ADP Antagonists
- Ticlopidine (Ticlid)
- Clopidogrel (Plavix)
- Aspirin/dipyridamole (Aggrenox)
- GIIb/IIIa Antagonists
- Abciximab (Reopro)
- Tirofiban (Aggrestat)
- Eptifibatide (Integrilin)
2
Q
COX-1 vs. COX-2: Platelet Function
A
-
COX-1: Produced by platelets
- No nuclei, so once inhibited, plts cannot produce more COX-1
- Induces platelet aggregation and vasoconstriction via thromboxane A2
-
COX-2: Produced by vascular endothelial cells
- Have nuclei, can replace inhibited enzyme
- Inhibits plt aggregation and promotes vasodilation via prostacylcin
3
Q
Aspirin Mechanism of Action (MOA)
A
- Arachidonic pathway uses cyclooxygenase (COX) to produce thromboxane A2 (TXA2) and prostacyclin I2 (PGI2)
- ASA irreversibly inhibits COX pathway
- 7-10 days (hold for this period before surgery unless risk of bleeding < benefit of continuing)
- TXA2 inhibition decreases vasoconstriction and decreases degranulation of platelets
- PGI2 inhibition reduces vasodilation and promotes platelet degranulation
- 7-10 days (hold for this period before surgery unless risk of bleeding < benefit of continuing)
4
Q
Aspirin
Doses
A
- Low doses (75 to 81 mg/day):
- irreversibly inhibit (COX)-1 → inhibits generation of thromboxane A2 → antithrombotic effect
- Intermediate doses (650 mg to 4 g/day):
- inhibit COX-1 and COX-2 → blocking prostaglandin (PG) production → analgesic and antipyretic effects
- High doses (4 and 8 g/day):
- anti-inflammatory effect - COX-2 dependent PGE2
- Limited by toxicity: tinnitus, hearing loss, and gastric intolerance
5
Q
Aspirin: Anti-platelet Indications
A
- Indications:
- TIA/ischemic stroke
- Stable and unstable angina
- Prevent/treat MI
- Maintenance of patent coronary stents
6
Q
Aspirin: Anti-platelet
Adverse Effects
A
- GI bleed
- Hemorrhagic stroke
7
Q
P2Y12 Adenosine Diphosphate (ADP) Receptor Antagonists: Thienopyridines
A
- Structurally related class of compounds reduce plt aggregation
-
Inhibition of the P2Y12 ADP receptor
- Blocks stimulated adenylyl-cyclase activity
-
Prodrugs: Converted in vivo to thiol-containing active metabolites
- Metabolism pathways are different for each member of this class
8
Q
ADP Receptor Antagonists:
Agents
A
-
Irreversible blockade for life of plt:
- 7-10 days
-
Ticlopidine – 1st generation
- Use less common
-
Clopidogrel – 2nd generation
- Most commonly used
-
Pasugrel – 3rd generation
- Black Box Warning for bleed risk in >75 year
- < 60 kg /TIA/Stroke patients
-
Reversible blockade:
- Ticagrelor
9
Q
ADP receptor antagonists: Clopidogrel
Indications
A
- Inhibits plt aggregation ~50%
- Maintenance of coronary stent patency
- Prevent MI/Stroke/vascular occlusion in high risk pts (usually combined w/ ASA in acute coronary syndromes)
- Alternative primary prevention in ASA intolerant pts
10
Q
ADP receptor antagonists: Clopidogrel
Pk
A
- Rapid oral absorption
- Onset 2 hrs
- Peak at 3-7 days
- Once daily dosing regimen considered sufficient
-
Pro-drug: Must undergo metabolism by CYP2C19 to become active
- “Poor metabolizers” (variant CYP2C19) may fail therapy; carries a Black Box Warning
- Consider prasugrel or ticagrelor in these pts
- “Poor metabolizers” (variant CYP2C19) may fail therapy; carries a Black Box Warning
11
Q
ADP receptor antagonists: Clopidogrel
Drug:Drug Interactions
A
- Other meds that increase bleeding
- Proton-pump inhibitors inhibit CYP2C19
-
Clopidogrel + aspirin vs aspirin alone: combo better
- Complimentary mechanisms → additive effect
- Effective for pts undergoing PCI and med mgmt
12
Q
ADP receptor antagonists: Clopidogrel
Adverse Reactions
A
- Severe rash
- Diarrhea
- Bleeding complications
- Thrombocytopenia (rate similar to aspirin)
- TTP – usually w/in first two weeks of therapy
- No significant rate of neutropenia (contrast with ticlopidine)
13
Q
Dipyridamole
Action, Pk
A
- A pyrimidopyrimidine derivative w/ vasodilator and antiplatelet properties
- MOA not clear
- Increases plasma adenosine levels
-
Half Life: 10 hrs
- Requires BID dosing
14
Q
Dipyridamole
Indication
A
- Used in combo w/ warfarin and indicated for prevention of thrombus following heart valve replacement
-
Aggrenox: Combined w/ aspirin to reduce risk of ischemic stroke
- FDA approved as combo med for stroke prevention
- No intrinsic antiplatelet activity or increased bleeding risk noted when used alone (w/o aspirin)
15
Q
Dipyridamole
Adverse Events
A
- Headache (most common)
- Nausea/dizziness
- Hypotension (vasodilator properties)
- Rash/flushing
- Bronchospasm/dyspnea
- Myocardial ischemia/infarction
- Arrhythmias